Purple Biotech Ltd. (PPBT) |
|
2.1 -0.02 (-0.94%)
|
03-17 15:59 |
|
Open: |
2.04 |
Pre. Close: |
2.12 |
|
High:
|
2.154 |
Low:
|
2.04 |
|
Volume:
|
28,052 |
Market Cap:
|
44(M) |
|
|
|
Technical analysis |
as of: 2023-03-20 7:48:36 AM |
|
Overall:
|
 |
| Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 2.76 One year: 3.23 |
| Support: |
Support1: 2.01 Support2: 1.78 |
| Resistance: |
Resistance1: 2.36 Resistance2: 2.76 |
| Pivot: |
2.13  |
| Moving Average: |
MA(5): 2.06 MA(20): 2.12 
MA(100): 1.86 MA(250): 2.33 |
| MACD: |
MACD(12,26): 0 Signal(9): 0 |
| Stochastic oscillator: |
%K(14,3): 42.9 %D(3): 38.7 |
| RSI: |
RSI(14): 53.5 |
| 52-week: |
High: 4.27 Low: 1.32 |
| Average Vol(K): |
3-Month: 48 (K) 10-Days: 46 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ PPBT ] has closed above bottom band by 42.1%. Bollinger Bands are 3.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
2.16 - 2.17 |
2.17 - 2.18 |
|
Low:
|
2.01 - 2.03 |
2.03 - 2.04 |
|
Close:
|
2.08 - 2.1 |
2.1 - 2.12 |
|
Company Description |
|
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug for cancer patients in the United States. Its oncology pipeline includes CM24, a monoclonal antibody that blocks carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 1b/2 clinical trials for the treatment of non-small cell lung cancer and pancreatic cancer; and NT219, a small molecule that targets insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment of recurrent and/or metastatic solid tumors and squamous cell carcinoma of the head and neck cancer. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company is headquartered in Rehovot, Israel. |
Headline News |
Tue, 14 Feb 2023
Purple Biotech Announces First Patient Dosed in Open Label ... - Yahoo Finance
Wed, 08 Feb 2023
Purple Biotech Reports Fourth Quarter and Full-Year 2022 Financial ... - GlobeNewswire
Thu, 02 Feb 2023
Purple Biotech rises 10% on acquisition of cancer therapy developer ... - Seeking Alpha
Tue, 03 Jan 2023
Purple Biotech and Mor Research Applications Announce Research ... - BioSpace
Sun, 27 Nov 2022
Is Purple Biotech (TLV:PPBT) In A Good Position To Deliver On Growth Plans? - Simply Wall St
Tue, 15 Nov 2022
Purple Biotech Presents New Data on Mechanism of Action for ... - GlobeNewswire
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
18 (M) |
| Shares Float |
0 (M) |
|
% Held by Insiders
|
0 (%) |
|
% Held by Institutions
|
0.6 (%) |
|
Shares Short
|
758 (K) |
|
Shares Short P.Month
|
832 (K) |
Stock Financials |
|
EPS
|
-0.77 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
3.94 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-19.7 |
|
Return on Equity (ttm)
|
-33.8 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
-0.01 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-1.13 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-16 (M) |
|
Levered Free Cash Flow
|
-8 (M) |
Stock Valuations |
|
PE Ratio
|
-2.73 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0.53 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-2.38 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
2020-08-20 |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
